Halozyme Therapeutics Inc... (HALO)
NASDAQ: HALO
· Real-Time Price · USD
54.53
0.78 (1.45%)
At close: May 23, 2025, 3:59 PM
54.45
-0.16%
After-hours: May 23, 2025, 05:55 PM EDT
1.45% (1D)
| Bid | 54.42 |
| Market Cap | 6.72B |
| Revenue (ttm) | 1.08B |
| Net Income (ttm) | 485.36M |
| EPS (ttm) | 3.76 |
| PE Ratio (ttm) | 14.5 |
| Forward PE | 7.5 |
| Analyst | Hold |
| Ask | 54.64 |
| Volume | 895,046 |
| Avg. Volume (20D) | 2,125,726 |
| Open | 53.23 |
| Previous Close | 53.75 |
| Day's Range | 53.03 - 54.66 |
| 52-Week Range | 42.01 - 70.51 |
| Beta | 1.26 |
About HALO
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol HALO
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for HALO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 week ago
-24.56%
Halozyme Therapeutics shares are trading lower aft...
Unlock content with
Pro Subscription
2 weeks ago
+18.12%
Halozyme Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 guidance. Also, Wells Fargo maintained an Equal-Weight rating on the stock and raised its price target from $60 to $65.
1 week ago · seekingalpha.com
Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper MoatHalozyme Therapeutics reported strong Q1 2025 earnings with a 35% revenue increase, 54% net income growth, and raised full-year guidance, reinforcing its status as a top biotech growth story. Key grow...
